Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
<p><b>Objective</b></p> Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. <p><b>Methods</b></p> T...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2024
|
| _version_ | 1817931326175576064 |
|---|---|
| author | Strand, V Gossec, L Coates, LC Ogdie, A Choi, J Becker, B Zhuo, J Lehman, T Nowak, M Elegbe, A Mease, PJ Deodhar, A |
| author_facet | Strand, V Gossec, L Coates, LC Ogdie, A Choi, J Becker, B Zhuo, J Lehman, T Nowak, M Elegbe, A Mease, PJ Deodhar, A |
| author_sort | Strand, V |
| collection | OXFORD |
| description | <p><b>Objective</b></p>
Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective.
<p><b>Methods</b></p>
This phase 2, double-blind trial (NCT03881059) randomized patients with active PsA 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo, for 16 weeks. Key secondary end points were changes from baseline (CFBs) at week 16 in Health Assessment Questionnaire-Disability Index (HAQ-DI) and 36-item Short-Form Health Survey (SF-36) physical component summary (PCS) scores. Additional patient-reported outcomes (PROs) assessed disease impact, including fatigue, pain, and mental health. The mean CFBs in PROs and percentages of patients reporting improvements with minimum clinically important differences (MCIDs) or scores of greater than normal values were also assessed.
<p><b>Results</b></p>
This study comprised 203 patients (51.2% female; mean ± SD age, 49.8 ± 13.5 years). At week 16, the adjusted mean difference (95% confidence interval) versus placebo in HAQ-DI and SF-36 PCS CFB was significant for each deucravacitinib group (HAQ-DI 6 mg, −0.26 [−0.42 to −0.10], P = 0.0020; HAQ-DI 12 mg, −0.28 [−0.45 to −0.12], P = 0.0008; SF-36 PCS 6 mg, 3.3 [0.9 to 5.7], P = 0.0062; SF-36 PCS 12 mg, 3.5 [1.1 to 5.9], P = 0.0042). MCID at week 16 were reported for all PROs with either dose of deucravacitinib. Improvements of MCID or to normative values were reported by more patients receiving deucravacitinib than placebo.
<p><b>Conclusion</b></p>
Deucravacitinib groups demonstrate significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA, which warrants further study. |
| first_indexed | 2024-03-07T08:29:05Z |
| format | Journal article |
| id | oxford-uuid:604a8acb-a858-4150-a7d5-834f42f73aa1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:20:14Z |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:604a8acb-a858-4150-a7d5-834f42f73aa12024-11-11T11:13:34ZImprovements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:604a8acb-a858-4150-a7d5-834f42f73aa1EnglishSymplectic ElementsWiley2024Strand, VGossec, LCoates, LCOgdie, AChoi, JBecker, BZhuo, JLehman, TNowak, MElegbe, AMease, PJDeodhar, A<p><b>Objective</b></p> Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. <p><b>Methods</b></p> This phase 2, double-blind trial (NCT03881059) randomized patients with active PsA 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo, for 16 weeks. Key secondary end points were changes from baseline (CFBs) at week 16 in Health Assessment Questionnaire-Disability Index (HAQ-DI) and 36-item Short-Form Health Survey (SF-36) physical component summary (PCS) scores. Additional patient-reported outcomes (PROs) assessed disease impact, including fatigue, pain, and mental health. The mean CFBs in PROs and percentages of patients reporting improvements with minimum clinically important differences (MCIDs) or scores of greater than normal values were also assessed. <p><b>Results</b></p> This study comprised 203 patients (51.2% female; mean ± SD age, 49.8 ± 13.5 years). At week 16, the adjusted mean difference (95% confidence interval) versus placebo in HAQ-DI and SF-36 PCS CFB was significant for each deucravacitinib group (HAQ-DI 6 mg, −0.26 [−0.42 to −0.10], P = 0.0020; HAQ-DI 12 mg, −0.28 [−0.45 to −0.12], P = 0.0008; SF-36 PCS 6 mg, 3.3 [0.9 to 5.7], P = 0.0062; SF-36 PCS 12 mg, 3.5 [1.1 to 5.9], P = 0.0042). MCID at week 16 were reported for all PROs with either dose of deucravacitinib. Improvements of MCID or to normative values were reported by more patients receiving deucravacitinib than placebo. <p><b>Conclusion</b></p> Deucravacitinib groups demonstrate significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA, which warrants further study. |
| spellingShingle | Strand, V Gossec, L Coates, LC Ogdie, A Choi, J Becker, B Zhuo, J Lehman, T Nowak, M Elegbe, A Mease, PJ Deodhar, A Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title | Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title_full | Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title_fullStr | Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title_full_unstemmed | Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title_short | Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial |
| title_sort | improvements in patient reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis results from a randomized phase 2 trial |
| work_keys_str_mv | AT strandv improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT gossecl improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT coateslc improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT ogdiea improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT choij improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT beckerb improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT zhuoj improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT lehmant improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT nowakm improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT elegbea improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT measepj improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial AT deodhara improvementsinpatientreportedoutcomesaftertreatmentwithdeucravacitinibinpatientswithpsoriaticarthritisresultsfromarandomizedphase2trial |